SCHEDULE 13G/A: Lance Friedman Discloses 9.08% Passive Stake in Aspire Biopharma Holdings

Lance Friedman has filed an amended Schedule 13G, reporting a 9.078% beneficial ownership stake in Aspire Biopharma Holdings, Inc. as of March 19, 2025.

Summary

• Lance Friedman beneficially owns 4,439,375 shares of Aspire Biopharma Holdings, Inc. common stock.
• This ownership represents 9.078% of the company's common stock.
• The shares include holdings by Blackstone Capital Advisors, Inc. (1,680,886 shares), Cobra Alternative Strategies LLC (2,095,989 shares), and Thor Special Situations LLC (662,500 shares).
• Mr. Friedman holds sole voting and sole dispositive power over all 4,439,375 shares.
• This filing is an Amendment No. 3 to a previously filed Schedule 13G, indicating a passive investment position.

Sentiment

Score: 6

Explanation: The filing is a standard disclosure of a significant passive ownership stake, which is generally neutral but can be seen as a vote of confidence by the investor.

Positives

• Lance Friedman, an individual, holds a significant passive stake of 9.078% in Aspire Biopharma Holdings, Inc., indicating a notable investment.

Negatives

• The filing does not contain any negative financial or operational information about Aspire Biopharma Holdings, Inc.

Risks

• The filing indicates a passive investment, meaning the reporting person does not intend to influence control of the issuer, which may limit active shareholder advocacy.

Future Outlook

NA

Industry Context

This Schedule 13G filing primarily concerns a change in beneficial ownership and does not provide specific details on broader industry trends within the biopharma sector.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant passive investor's stake, which may offer some confidence.

Key Dates

Keywords

Aspire Biopharma Holdings, Lance Friedman, Schedule 13G, beneficial ownership, common stock, passive investment, SEC filing, biopharma